- Open Access
Intensity modulated radiotherapy (IMRT) in benign giant cell tumors – a single institution case series and a short review of the literature
© Roeder et al; licensee BioMed Central Ltd. 2010
- Received: 10 December 2009
- Accepted: 26 February 2010
- Published: 26 February 2010
Giant cell tumors are rare neoplasms, representing less than 5% of all bone tumors. The vast majority of giant cell tumors occurs in extremity sites and is treated by surgery alone. However, a small percentage occurs in pelvis, spine or skull bones, where complete resection is challenging. Radiation therapy seems to be an option in these patients, despite the lack of a generally accepted dose or fractionation concept. Here we present a series of five cases treated with high dose IMRT.
Patients and Methods
From 2000 and 2006 a total of five patients with histologically proven benign giant cell tumors have been treated with IMRT in our institution. Two patients were male, three female, and median age was 30 years (range 20 -- 60). The tumor was located in the sacral region in four and in the sphenoid sinus in one patient. All patients had measurable gross disease prior to radiotherapy with a median size of 9 cm. All patients were treated with IMRT to a median total dose of 64 Gy (range 57.6 Gy to 66 Gy) in conventional fractionation.
Median follow up was 46 months ranging from 30 to 107 months. Overall survival was 100%. One patient developed local disease progression three months after radiotherapy and needed extensive surgical salvage. The remaining four patients have been locally controlled, resulting in a local control rate of 80%. We found no substantial tumor shrinkage after radiotherapy but in two patients morphological signs of extensive tumor necrosis were present on MRI scans. Decline of pain and/or neurological symptoms were seen in all four locally controlled patients. The patient who needed surgical salvage showed markedly reduced pain but developed functional deficits of bladder, rectum and lower extremity due to surgery. No severe acute or late toxicities attributable to radiation therapy were observed so far.
IMRT is a feasible option in giant cells tumors not amendable to complete surgical removal. In our case series local control was achieved in four out of five patients with marked symptom relief in the majority of cases. No severe toxicity was observed.
- Clinical Target Volume
- Local Control Rate
- Giant Cell Tumor
Giant cell tumors of bone are usually benign tumors, however they can be locally aggressive and in some cases malignant transformation or metastatic disease occurs [1, 2]. They account for approximately 5% of all primary bone tumors and about 20% of benign bone tumors . The majority of these tumors is located in the long bones of the extremities, however a small proportion (< 10%) occurs in the pelvis, spine or skull base [1, 2]. Usually patients present with small lesions after a brief history of swelling or pain but especially in the sacral region, giant cell tumors can reach an enormous size and result in massive pain in combination with severe neurological deficits. The standard of care for giant cell tumors is function-preserving surgery . After complete resection, local control is achieved in 85-90% of all cases , but incomplete resection is frequently associated with tumor recurrence in up to 50% of the cases . Despite the improvements in surgical techniques, complete tumor removal without major functional deficits remains challenging in some regions, especially sacral or pelvic bones, spine or skull base . Therefore primary radiotherapy has been advocated as an alternative treatment in patients suffering from giant cell tumors in these regions, although concerns about local side effects of radiotherapy with appropriate doses have been raised in the past [5, 6]. As radiotherapy techniques have extensively evolved in the last decades, including the development of three-dimensional conformal radiotherapy with megavoltage energies and even intensity-modulated and image-guided radiotherapy, the possibility to apply high doses with less toxicity and optimal sparing of critical structures is now widely available. Here we report our experience with intensity-modulated radiotherapy in the treatment of giant cell tumors occurring outside the extremities in combination with a short review of the literature.
Patients, treatment and outcome
No residual symptoms
All patients were followed with clinical examination and MRI scans in our institution or the referring hospital on a regular basis. Median follow up was 46 months, ranging from 30 to 107 months.
Local control and salvage surgery
Four out of five patients have been locally controlled without clinical or radiographic signs of progression, resulting in an overall local control rate of 80%. One patient with a biopsy proven primary giant cell tumor of the sacral region developed a progression of clinical symptoms in the meaning of pain, paralysis of the leg and bladder/rectal dysfunction without tumor progression on MRI scan three months after radiotherapy. She received salvage surgery which included complete removal of the tumor and is currently alive without evidence of disease and marked pain relief, but suffers from impaired extremity function, complete loss of bladder function and a permanent descendostoma.
Acute toxicity related to the radiation treatment was of minor grade in all cases. No acute toxicity of grade > 1 according to RTOG was observed. In detail, three patients suffered from mild skin erythema, one from mild alopecia, one from diarrhea, one from urgency and one from mild conjunctivitis. All acute toxicities resolved spontaneously. Beside from mild skin hyperpigmentation in the irradiated areas in two patients, no late toxicities attributable to radiation therapy were observed so far.
Reduction of pain was observed in four out of five patients already during radiotherapy. Considering the long term follow up excluding the patient with salvage surgery three months after radiotherapy, one patient showed a minor, two patients a major improvement of their symptoms and one patient is free of symptoms. Improvement included not only reduced pain but also a decrease of the sensory neurological deficits in two patients.
The mainstay of treatment of giant cell tumors of the bone is complete surgical excision. Especially in patients with extremity tumors, this treatment results in high local control rates of more than 85%  without major complications or functional deficits. However, a small proportion of patients suffers from large giant cell tumors of sacral bone, spine or skull base. In these regions of the body, complete surgical removal without major functional deficits is challenging or sometimes impossible and recurrence rates of about 50% have been reported after surgical treatment with intralesional margins . Systemic treatment options are limited, although there seems to be some progress through improved understanding of the molecular mechanisms in the development of giant cell tumors. As they are rich in stromal cells that express RANKL, a key mediator of osteoclast activation , increasing interest has been paid to monoclonal antibodies against RANKL, for example denosumab. A pilot study in 37 patients showed a response rate of 86% and functional improvements including reduced pain in 84% of the patients suffering from giant cell tumors treated with denosumab . However, no long term data about the recurrence rate, functional outcome and long term toxicity with this promising approach exists so far and therefore further investigation is needed to establish the value of this treatment option. Therefore primary radiotherapy has to be considered as an alternative treatment in patients with giant cell tumors not suitable for complete resection, although based on small patient series, collected over long time periods, with wide variations in fractionation, total dose and radiation techniques [1–4, 15–20].
Beside the limited data for this treatment approach, radiotherapy has been criticized in the past also because of low rates of local control in some series and concerns about side effects and induction of malignant transformation [2, 5, 6]. Careful examination reveals that many of these series have been conducted in the 2-D era of radiotherapy and radiodiagnostics more than 15 years ago. This implicates not only a high possibility for geographical misses due to the use of plain radiographs for tumor localisation, which could have resulted in decreased coverage of the tumors by radiation therapy and therefore decreased local control, but also the use of orthovoltage techniques with low energies, resulting in high toxicity due to the unfavourable dose distribution and probably increased rates of secondary malignancies .
Considering the issue of malignant transformation, these concerns regarding radiation therapy, have mainly been based on initial reports of transformation rates up to 24% . Other series using more modern radiotherapy techniques found lower rates of 0-11% [1, 4] and a recent metaanalysis reported an incidence of less than 1% in patients treated with megavoltage radiation and modern radiation therapy techniques . Beside that, malignant transformation and sarcoma induction have also been reported in patients treated without radiation at all. For example Dahlin et al.  reported the development of sarcoma in 2 of 47 (4%) patients and Mnaymneh et al.  even in 2 of 25 (8%) patients after surgery. The appearance of malignant giant cell tumors of bone or malignant foci inside benign giant cell tumors has been described also in a small number of patients [24, 25], and pulmonary metastases can be found in 2-9% of patients with benign giant cell tumors [5, 26–28]. Thus malignant transformation or the appearance of metastases could be part of the disease itself in a small proportion of cases and should not be attributed unreflected to radiation treatment.
To date there is no generally accepted fractionation or dose concept for the treatment of giant cell tumors. A clear dose-effect relationship has not been established yet, but in some series higher doses resulted in increased local control rates. For example, Feigenberg et al.  found a significant increased local control rate of 86% with doses above 40 Gy compared to 67% with lower doses. In contrast, Leggon et al.  did not find a benefit in terms of local control comparing doses of < 45 Gy, 45-55 Gy and > 55 Gy in pelvic and sacral lesions, but the overall local control rate in their series was only about 50%. Malone et al.  found a local control rate of 83% in non-extremity lesions even using doses as low as 35 Gy in 15 fractions. In our patients, we attempted doses of 60-66 Gy, a dose range which could be safely administered without major toxicities based on our experiences in treating other sacral lesions like chordoma or low grade chondrosarcoma using IMRT in order to achieve maximal local control. Although a wide dose range was reported in most of the series, careful examination leads to the impression that usually patients with radiation as sole treatment and non-extremity lesions were treated with higher doses. However, if dose escalation beyond doses of 45 Gy increases local control, remains an open question based on the available data.
Considering the clinical outcome of patients with giant cell tumors treated by radiotherapy, only little information is available in the literature. For example in the series of Schwartz et al. , only three of thirteen patients had neurological symptoms before treatment. All three patients showed improved neurological function after radiation therapy. Malone et al.  reported 7 patients with symptomatic disease before radiotherapy, all have been ambulatory and independent after treatment. In our series, all patients suffered from pain and/or neurological deficits prior to radiotherapy. After treatment, all patients showed some kind of improvement except the patient who needed salvage surgery three months after radiotherapy. One of the four patients is free of symptoms, two had major improvements and one a minor improvement. Thus radiotherapy cannot only stop the locally destructive growth of giant cell tumors but also decreases pain and other neurological symptoms of the patients resulting in improved quality of life.
Considering the radiographic outcome of giant cell tumors after radiotherapy, the available information in the literature is even more scanty than for clinical outcome. This may be linked to the use of two-dimensional radiographs for diagnosis and follow up in most of the older series. The appearance of bone sclerosis after radiotherapy in most cases has been described by Seider et al. , and tumor response in terms of involution or ossification was observed in 4 of 9 patients in the series reported by Leggon et al. . In our series, MRI was used for diagnostics and regular follow up in all patients. In contrast to the mentioned results, we did not find significant tumor volume shrinkage after treatment. However, the absence of significant volume reduction is a common feature of benign lesions treated by radiotherapy, as shown in many other entities like meningioma, desmoids or chordoma [29–31] and should not be interpreted as a failure of treatment.
Radiotherapy carried out by modern techniques based on modern imaging could be an alternative treatment approach in patients with giant cell tumors not amendable to function-preserving surgery. High local control rates without severe acute or late side effects and improvement in clinical symptoms are achievable in the majority of patients.
- Feigenberg SJ, Marcus RB, Zlotecki RA, Scarborough MT, Berrey BH, Enneking WF: Radiation Therapy for Giant cell tumors of bone. Clin Orthop Rel Res 2003, 411: 207-16. 10.1097/01.blo.0000069890.31220.b4View ArticleGoogle Scholar
- Malone S, O'Sullivan B, Catton C, Bell R, Fornasier V, Davis A: Long-term follow up of efficiacy and safety of megavoltage radiotherapy in hihg-risk giant cell tumors of bone. Int J Radiat Biol Oncol Phys 1995, 33: 689-694. 10.1016/0360-3016(95)00159-VView ArticleGoogle Scholar
- Seider MJ, Rich TA, Ayala AG, Murray J: Giant cell Tumor of bone: treatment with radiation therapy. Radiology 1986, 161: 537-540.View ArticlePubMedGoogle Scholar
- Leggon RE, Zlotecki R, Reith J, Scarborough MT: Giant cell tumor of the pelvis and sacrum. Clin Orthop Rel Res 2004, 423: 196-207. 10.1097/01.blo.0000128643.38390.07View ArticleGoogle Scholar
- Goldenberg RR, Campbell CJ, Bonfiglio M: Giant cell tumor of bone: An analysis of two hundred and eighteen cases. J Bone Joint Surg 1970, 52: 619-664.PubMedGoogle Scholar
- McGrath PJ: Giant-cell tumor ofbone: An analysis of fifty-two cases. J Bone Joint Surg 1972, 54: 216-224.Google Scholar
- Schlegel W, Kneschaurek P: Inverse radiotherapy planning. Strahlenther Onkol 1999, 175: 197-207. 10.1007/BF02742396View ArticlePubMedGoogle Scholar
- Schad LR, Gademann G, Knopp M, Zabel HJ, Schlegel W, Lorenz WJ: Radiotherapy treatment planning of basal meningiomas: improved tumor localization by correlation of CT and MR imaging data. Radiother Oncol 1992, 25: 56-62. 10.1016/0167-8140(92)90196-2View ArticlePubMedGoogle Scholar
- Debus J, Engenhart-Cabillic R, Knopp MV, Schad LR, Schlegel W, Wannenmacher M: Image-oriented planning of minimally invasive conformal irradiation of the head-neck area. Radiologe 1996, 36: 732-6. 10.1007/s001170050135View ArticlePubMedGoogle Scholar
- Münter MW, Thilmann C, Hof H, Didinger B, Rhein B, Nill S, Schlegel W, Wannenmacher M, Debus J: Stereotactic intensity modulated radiation therapy and inverse treatment planning for tumors of the head and neck region: clinical implementation of the step and shoot approach and first clinical results. Radiother Oncol 2003, 66: 313-21. 10.1016/S0167-8140(03)00021-5View ArticlePubMedGoogle Scholar
- Pirzkall A, Debus J, Haering P, Rhein B, Grosser KH, Höss A, Wannenmacher M: Intensity modulated radiotherapy (IMRT) for recurrent, residual, or untreated skull-base meningiomas: preliminary clinical experience. Int J Radiat Oncol Biol Phys 2003, 55: 362-72.View ArticlePubMedGoogle Scholar
- Pirzkall A, Carol M, Lohr F, Höss A, Wannenmacher M, Debus J: Comparison of intensity-modulated radiotherapy with conventional conformal radiotherapy for complex-shaped tumors. Int J Radiat Oncol Biol Phys 2000, 48: 1371-80. 10.1016/S0360-3016(00)00739-2View ArticlePubMedGoogle Scholar
- Münter MW, Nill S, Thilmann C, Hof H, Höss A, Häring P, Partridge M, Manegold C, Wannenmacher M, Debus J: Stereotactic intensity-modulated radiation therapy (IMRT) and inverse treatment planning for advanced pleural mesothelioma. Feasibility and initial results. Strahlenther Onkol 2003, 179: 535-41. 10.1007/s00066-003-1055-7View ArticlePubMedGoogle Scholar
- Thomas DM, Chawla S, Skubitz K, Staddon A, Henshaw R, Blay J, Smith J, Ye Z, Roudier M, Jun S: Denosumab for the treatment of giant cell tumor (GCT) of bone: Final results from a proof-of-concept, phase II study [abstract]. J Clin Oncol 2009, 27: s15. 10.1200/JCO.2008.18.3301View ArticleGoogle Scholar
- Schwartz LH, Okunieff PG, Rosenberg A, Suit HD: Radiation therapy in the treatment of difficult giant cell tumors. Int J Radiat Biol Oncol Phys 1989, 17: 1089-1095.View ArticleGoogle Scholar
- Chen ZX, Gu DZ, Yu ZH, Qian TN, Huang YR, Hu YH, Gu XZ: Radiation therapy of giant cell tumor of bone: Analysis of 35 patients. Int J Radiat Oncol Biol Phys 1986, 12: 329-334.View ArticlePubMedGoogle Scholar
- Daugaard S, Johansen HF, Barfod G, Laustein G, Schiødt T, Lund B: Radiation treatment of giant-cell tumor of bone (osteoclastoma). Acta Oncol 1987, 26: 41-43. 10.3109/02841868709092976View ArticlePubMedGoogle Scholar
- Nair MK, Jyothirmayi R: Radiation therapy in the treatment of giant cell tumor of bone. Int J Radiat Oncol Biol Phys 1999, 43: 1065-1069. 10.1016/S0360-3016(98)00526-4View ArticlePubMedGoogle Scholar
- Chakravarti A, Spiro IJ, Hug EB, Mankin HJ, Efird JT, Suit HD: Megavoltage radiation therapy for axial and inoperable giant-cell tumor of bone. J Bone Joint Surg 1999 81: 1566-1573.PubMedGoogle Scholar
- Miszczyk L, Wydmanski J, Spindel J: Efficacy of radiotherapy for giant cell tumor of bone: given either postoperatively or as sole treatment. Int J Radiat Oncol Biol Phys 2001, 49: 1239-1242.View ArticlePubMedGoogle Scholar
- Harwood AR, Fornasier VL, Rider WD: Supervoltage irradiation in the management of giant cell tumors of bone. Radiology 1977, 125: 223-226.View ArticlePubMedGoogle Scholar
- Dahlin DC, Cupps RE, Johnson EW: Giant-cell tumors: A study of 195 cases. Cancer 1970, 25: 1061-1070. 10.1002/1097-0142(197005)25:5<1061::AID-CNCR2820250509>3.0.CO;2-EView ArticlePubMedGoogle Scholar
- Mnaymneh WA, Dudley HR, Mnaymneh LG: Giant-cell tumor of bone: An analysis and follow-up study of the forty-one cases observed at the Massachusetts general Hospital between 1925 and 1960. J Bone Joint Surg 1964, 46: 63-75.PubMedGoogle Scholar
- Witrak GA, Unii KK, Sim FH, Beabout JW, Dahlin DC: Malignant giant cell tumor of bone [abstract]. Lab Invest 1979, 40: 292.Google Scholar
- Nacimento AG, Huvos AG, Marcone RC: Primary malignant giant cell tumor of bone. Cancer 1979, 48: 1393-1402. 10.1002/1097-0142(197910)44:4<1393::AID-CNCR2820440433>3.0.CO;2-ZView ArticleGoogle Scholar
- Kay RM, Eckardt JJ, Seeger LL, Mirra JM, Hak DJ: Pulmonary metastasis of benign giant cell tumor of bone: six histologically confirmed cases, including one of spontaneous regression. Clin Orthop 1994, 302: 219-230.PubMedGoogle Scholar
- Rock MG, Pritchard DJ, Unni KK: Metastases from histologically benign giant-cell tumors of bone. J Bone Joint Surg 1984, 66: 269-274.PubMedGoogle Scholar
- Sung HW, Kuo DP, Shu WP, Chai YB, Liu CC, Li SM: Giant-cell tumor of bone: Analysis of two hundred and eight cases in Chinese patients. J Bone Joint Surg 1982, 64: 755-761.PubMedGoogle Scholar
- Milker-Zabel S, Zabel A, Schulz-Ertner D, Schlegel W, Wannenmacher M, Debus J: Fractionated stereotactic radiotherapy in patients with benign or atypical intracranial meningioma: long-term experience and prognostic factors. Int J Radiat Oncol Biol Phys 2005, 61: 809-816.View ArticlePubMedGoogle Scholar
- Rüdiger HA, Ngan SY, Ng M, Powell GJ, Choong PF: Radiation therapy in the treatment of desmoid tumors reduces surgical indications. Eur J Surg Oncol 2009, in press.Google Scholar
- Henderson FC, McCool K, Seigle J, Jean W, Harter W, Gagnon GJ: Treatment of chordomas with CyberKnife: Georgetown university experience and treatment recommendations. Neurosurgery 2009,64(2 suppl):A44-53. 10.1227/01.NEU.0000341166.09107.47View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.